Board of the Pension Protection Fund Acquires Shares of 1,600 Insulet Co. (NASDAQ:PODD)

Board of the Pension Protection Fund acquired a new position in Insulet Co. (NASDAQ:PODDFree Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,600 shares of the medical instruments supplier’s stock, valued at approximately $418,000.

Other large investors also recently made changes to their positions in the company. Baillie Gifford & Co. lifted its position in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after buying an additional 389,639 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Clearbridge Investments LLC increased its holdings in shares of Insulet by 6.0% in the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares during the last quarter.

Insider Activity

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.47% of the stock is currently owned by company insiders.

Insulet Stock Down 0.4 %

NASDAQ:PODD opened at $267.04 on Wednesday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The stock has a 50-day moving average price of $264.57 and a two-hundred day moving average price of $230.93. The stock has a market cap of $18.73 billion, a price-to-earnings ratio of 45.73, a PEG ratio of 4.12 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent research reports. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Canaccord Genuity Group raised their target price on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Sanford C. Bernstein started coverage on shares of Insulet in a research note on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $272.81.

Get Our Latest Report on Insulet

Insulet Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Recommended Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.